RenovoRx(RNXT)

MOUNTAIN VIEW, CAMedical Devices1 H-1B visas (FY2023)

Focus: RenovoRx is a public medical device company specializing in catheter-based local drug delivery systems for oncology, particularly pancreatic cancer. The company is pre-revenue with minimal commercial traction and a highly experimental pipeline.

Oncology

Profile data last refreshed 7h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About RenovoRx

AI assessmentNot Hiring

No open roles listed right now. Follow RenovoRx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$43K

Pipeline & Clinical Trials

RenovoCath™ R120 Catheter

Pancreatic Neoplasms

N/A

Clinical Trials (1)

NCT02591082Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter

N/A

Help build intelligence for RenovoRx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Recently secured FDA orphan drug designation for oxaliplatin in pancreatic cancer (May 2026), signaling regulatory validation of the platform approach.
Focused pipeline with 4 active programs targeting solid tumors and pancreatic cancer, including a Phase 3 program that could accelerate development timelines.
Dual-track innovation combining proprietary catheter hardware (RenovoCath) with chemotherapy payload delivery, offering device-pharma hybrid career exposure.

Watch Out For

Severe financial distress: $43K revenue against $6M R&D spend and $8.8M net loss (FY 2025); cash position deteriorated from $1M to $7M YoY, indicating capital raising dependency.
Zero current hiring and no active job openings despite public status; extremely limited team growth and career mobility within the company.
Pre-commercialization stage with no marketed products; career stability depends entirely on successful Phase 3 readout and regulatory approval with significant execution risk.

Generated by Claude from RenovoRx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RenovoCath®

Solid Tumors

N/A

Clinical Trials (1)

NCT06805461PumaRx Registry Trial

N/A

Gemcitabine, local delivery

Pancreatic Cancer

PHASE_1

Clinical Trials (1)

NCT02237157A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

Phase 1

Gemcitabine

Locally Advanced Pancreatic Cancer

PHASE_3

Clinical Trials (1)

NCT03257033Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

H-1B (2023): 1 approval

Publications: 3 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$43K0%

R&D Spend

$6M(14012%)6%

Net Income

-$9M

Cash

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(3)

Recent peer-reviewed publications with author affiliations at this company

Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch.

Radiology case reports

2026

PMID:42111415

Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2.